Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Fosun Pharmaceutical (Group) Co's operating cash flow per share for the
three
months ended in Jun. 2026 was $0.07.
Shanghai Fosun Pharmaceutical (Group) Co's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.30.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Shanghai Fosun Pharmaceutical (Group) Co was 17.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 6.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 10.10% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 8.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
SFOSF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -19.9 Med: 10.3 Max: 61.4
Current: 6.7
During the past 13 years, Shanghai Fosun Pharmaceutical (Group) Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was 61.40% per year. The lowest was -19.90% per year. And the median was 10.30% per year.
SFOSF's 3-Year OCF Growth Rate is ranked worse than 51.05% of 760
companies
in the Drug Manufacturers industry
Industry Median: 7.25
vs SFOSF: 6.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Operating Cash Flow per Share Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
SFOSF vs ZTS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.30 mean?
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Operating Cash Flow per Share of $0.30 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #388 out of 760 companies in the Drug Manufacturers industry, placing it in the top 51.1%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Operating Cash Flow per Share too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Operating Cash Flow per Share is $0.30. The Drug Manufacturers industry median Operating Cash Flow per Share is 7.25. Shanghai Fosun Pharmaceutical (Group) Co's value of $0.30 is 95.9% below this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #388 out of 760 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Operating Cash Flow per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #388 out of 760 companies for Operating Cash Flow per Share. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.25. Shanghai Fosun Pharmaceutical (Group) Co's value of $0.30 is 95.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.25, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Operating Cash Flow per Share of $0.30 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Operating Cash Flow per Share is $0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.20 — trading 14.7% below its estimated fair value. The current Operating Cash Flow per Share is $0.30 and 95.9% below the Drug Manufacturers industry median of 7.25. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Operating Cash Flow per Share is $0.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 14.7% below its estimated GF Value™ of $2.58.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
Operating Cash Flow per Share: $0.30
GF Value™: $2.58 vs. price of $2.20 (14.7% below fair value)
Industry Position: 95.9% below the Drug Manufacturers median (#388 of 760)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SFOSF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
